Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Revenues	$ 30,449	$ 15,173	$ 76,673	$ 24,649
Operating expenses:
Cost of products sold	3,964	1,744	$ 9,463	$ 2,704
Cost, product and service, extensible enumeration			FOTIVDA U.S. product revenue, net	FOTIVDA U.S. product revenue, net
Research and development	11,074	7,502	$ 33,552	$ 20,177
Selling, general and administrative	17,579	15,142	51,991	45,162
Operating expenses	32,617	24,388	95,006	68,043
Loss from operations	(2,168)	(9,215)	(18,333)	(43,394)
Other income (expense), net:
Interest expense, net	(1,098)	(1,153)	(3,451)	(2,892)
Change in fair value of PIPE Warrant liability	0	0	0	199
Other income (expense), net	(1,098)	(1,153)	(3,451)	(2,693)
Net loss	$ (3,266)	$ (10,368)	$ (21,784)	$ (46,087)
Basic and diluted net loss per share:
Net loss per share - basic (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.63)	$ (1.44)
Net loss per share - diluted (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.63)	$ (1.44)
Weighted average number of common shares outstanding - basic (in shares)	34,618	34,374	34,533	32,081
Weighted average number of common shares outstanding - diluted (in shares)	34,618	34,374	34,533	32,081
FOTIVDA U.S. product revenue, net
Revenues:
Revenues	$ 30,190	$ 14,318	$ 75,282	$ 22,119
Partnership licensing and royalty revenue
Revenues:
Revenues	$ 259	$ 855	$ 1,391	$ 2,530